businesswire.com
Vicarious Surgical Advances Toward Design Freeze with Successful In-Vivo Porcine Lab
WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical (NYSE: RBOT) (the “Company”), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the successful completion of an in-vivo porcine lab conducted in December 2025, marking a meaningful step forward in the development of the company's robotic system and reinforcing progress toward system design freeze targeted for the end of 2026. During the lab, surgeons independently completed.
